Michael D. Tucker

Represented privately-held U.S. real estate investment firm on multiple private equity fund formations.

Represented privately-held U.S. real estate investment firm on multiple joint venture agreements with various development partners.

Represented privately-held for-profit school in various tax credit transactions.

Represented Canadian pension fund in the acquisition of interests in a U.S. portfolio of multi-family properties.

Represented Canadian pension fund in the acquisition of interests in a U.S. portfolio of industrial properties.

Represented Canadian investment manager in the acquisition of interests in a U.S. portfolio of multi-family properties.

Represented specialty lender in acquisition and divestiture of manufactured home floor plan financing portfolio.

Represented early-stage, oncology-focused life sciences company in private offering of securities.

Represented drug development services provider in private offering of securities.

Represented U.S. pharmaceutical manufacturer in asset dispositions of various branded over-the-counter products.

Represented publicly traded hospital-focused real estate investment trust on numerous transactions ranging in value up to $2 billion.

Represented clinical-stage sponsor in collaboration agreement for the development of a companion diagnostic product.

Represent global pharmaceutical manufacturer in all aspects of U.S. and ex-U.S. clinical trials (phases I-III) for various oncology products including contract negotiations with contract research organizations (CRO) and other vendors and service providers.

Represented urgent care practice management company in de novo formation and private offering of securities.

Represented urgent care practice management company in corporate restructuring.

Represented urgent care practice in de novo formation and regulatory compliance.

Represented nationwide mail order pharmacy in de novo formation and recapitalization.

Represented clinical diagnostic laboratory in corporate restructuring.

Represented early-stage Israeli medical device company in a U.S. clinical trial for experimental breast cancer detection equipment.

Represent dedicated clinical research site in its de novo formation, in contract negotiation with sponsors and vendors, and in all general corporate matters.

Represent medical device manufacturer in all aspects of U.S. pilot and pivotal medical device clinical trials including contract negotiations with CROs and other vendors and service providers.

Represented clinical-stage sponsor in phase I clinical trial for development of a cancer immunotherapy.

Represented clinical-stage sponsor in Collaboration and Clinical Supply Agreement with large U.S. pharmaceutical manufacturer for development of cancer immunotherapies.

Represented clinical-stage sponsor in Clinical Supply Agreement with large European pharmaceutical manufacturer for development of cancer immunotherapies.

Represent large, multi-office, single-specialty medical practice in all aspects of clinical research contracting.

Represented clinical trial site management organization in de novo formation.

Represented U.S. biotechnology company in U.S. and ex-U.S. phases II and III global clinical trials for anti-viral therapy.

Represented anatomic pathology laboratory in negotiation of master services agreement with CRO.